cytarabine has been researched along with abt 869 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Albert, DH; Bi, C; Chen, CS; Davidsen, SK; Glaser, KB; Han, JH; Lilly, M; Lim, YP; Loh, SL; Pan, M; Tai, YC; Xie, Z; Zhou, J | 1 |
| Albert, DH; Carlson, DM; Dudley, M; Enschede, S; Glaser, K; Hogge, D; Koh, LP; Li, X; McKeegan, E; Pradhan, R; Stock, W; Wang, ES; Yee, K | 1 |
1 trial(s) available for cytarabine and abt 869
| Article | Year |
|---|---|
Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; fms-Like Tyrosine Kinase 3; Humans; Indazoles; Leukemia, Myeloid, Acute; Male; Middle Aged; Phenylurea Compounds; Recurrence; Treatment Outcome | 2012 |
1 other study(ies) available for cytarabine and abt 869
| Article | Year |
|---|---|
Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathway.
Topics: Acute Disease; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Proteins; Cytarabine; Down-Regulation; Doxorubicin; Drug Synergism; Drug Therapy, Combination; Gene Expression Profiling; Humans; Indazoles; Leukemia, Myeloid; Mice; Mice, SCID; Mitogen-Activated Protein Kinases; Phenylurea Compounds; Proto-Oncogene Proteins c-mos; Receptor Protein-Tyrosine Kinases; RNA, Small Interfering; Signal Transduction; Transplantation, Heterologous | 2008 |